Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Clinical activity in the dose-expansion phase (confirmed responses per investigator assessment).</p>
Na minha lista:
Registros relacionados
-
Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025) -
Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025) -
Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025) -
Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025) -
Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025)